Lilly to file for accelerated FDA approval of Alzheimer's drug (donanemab) after Aduhelm OK opens the floodgates

Source

Welp, here we are. The norms have been broken, and there are 6 million plus patients out there all worth $56,000 per year.

Quite a few people on here suspected this would be the case, but I never dreamed it would be THIS fast.

Next up is Roche/Genentech with gantenerumab filing for accelerated approval. Heck, let's resurrect solanezumab while we are at it.

​

EDIT: Oh, and donanemab was just granted breakthrough designation.